🚀 VC round data is live in beta, check it out!
Lifeward Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lifeward and similar public comparables like AnteoTech, European Medical Solutions, Promimic, Harvard Bioscience and more.
Lifeward Overview
About Lifeward
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.
Founded
2001
HQ
Employees
80
Website
Financials (LTM)
EV
$27M
Lifeward Financials
Lifeward reported last 12-month revenue of $24M.
In the same LTM period, Lifeward generated $10M in gross profit and had net loss of ($19M).
Revenue (LTM)
Lifeward P&L
In the most recent fiscal year, Lifeward reported revenue of $22M and EBITDA of ($17M).
Lifeward expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $24M | XXX | $22M | XXX | XXX | XXX |
| Gross Profit | $10M | XXX | $8M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 38% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($17M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (75%) | XXX | XXX | XXX |
| EBIT Margin | (62%) | XXX | (69%) | XXX | XXX | XXX |
| Net Profit | ($19M) | XXX | ($20M) | XXX | XXX | XXX |
| Net Margin | (77%) | XXX | (90%) | XXX | XXX | XXX |
| Net Debt | — | — | $634K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lifeward Stock Performance
Lifeward has current market cap of $25M, and enterprise value of $27M.
Market Cap Evolution
Lifeward's stock price is $6.64.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $27M | $25M | 0.9% | XXX | XXX | XXX | $-5.26 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLifeward Valuation Multiples
Lifeward trades at 1.1x EV/Revenue multiple, and (1.7x) EV/EBITDA.
EV / Revenue (LTM)
Lifeward Financial Valuation Multiples
As of April 11, 2026, Lifeward has market cap of $25M and EV of $27M.
Equity research analysts estimate Lifeward's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lifeward has a P/E ratio of (1.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $25M | XXX | $25M | XXX | XXX | XXX |
| EV (current) | $27M | XXX | $27M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.7x) | XXX | XXX | XXX |
| EV/EBIT | (1.8x) | XXX | (1.8x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | 3.2x | XXX | XXX | XXX |
| P/E | (1.3x) | XXX | (1.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lifeward Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Lifeward Margins & Growth Rates
Lifeward's revenue in the last 12 month grew by 49%.
Lifeward's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Lifeward Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 49% | XXX | 37% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (75%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 58% | XXX | 63% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 36% | XXX | 37% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 115% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Lifeward Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| European Medical Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Promimic | XXX | XXX | XXX | XXX | XXX | XXX |
| Harvard Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Cambridge Cognition | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lifeward M&A Activity
Lifeward acquired XXX companies to date.
Last acquisition by Lifeward was on XXXXXXXX, XXXXX. Lifeward acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Lifeward
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLifeward Investment Activity
Lifeward invested in XXX companies to date.
Lifeward made its latest investment on XXXXXXXX, XXXXX. Lifeward invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Lifeward
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lifeward
| When was Lifeward founded? | Lifeward was founded in 2001. |
| Where is Lifeward headquartered? | Lifeward is headquartered in United States. |
| How many employees does Lifeward have? | As of today, Lifeward has over 80 employees. |
| Who is the CEO of Lifeward? | Lifeward's CEO is William Mark Grant. |
| Is Lifeward publicly listed? | Yes, Lifeward is a public company listed on Nasdaq. |
| What is the stock symbol of Lifeward? | Lifeward trades under LFWD ticker. |
| When did Lifeward go public? | Lifeward went public in 2014. |
| Who are competitors of Lifeward? | Lifeward main competitors are AnteoTech, European Medical Solutions, Promimic, Harvard Bioscience. |
| What is the current market cap of Lifeward? | Lifeward's current market cap is $25M. |
| What is the current revenue of Lifeward? | Lifeward's last 12 months revenue is $24M. |
| What is the current revenue growth of Lifeward? | Lifeward revenue growth (NTM/LTM) is 49%. |
| What is the current EV/Revenue multiple of Lifeward? | Current revenue multiple of Lifeward is 1.1x. |
| Is Lifeward profitable? | No, Lifeward is not profitable. |
| What is the current net income of Lifeward? | Lifeward's last 12 months net income is ($19M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.